Curious to know if TRK kinases as the targets would evolve and resist this novel approach, I wanted to re-blog and get some views on this. This approval must be based on their inability to develop alternate pathways. Makes one hope that management of the inoperable glioblastoma multiforme is now within reach! Thank you for the article on Altiratinib!
That it targets four very active participants is exciting and scary. Is it often that such an approach could have long term effects?
RePress from Dr. Melvin Crasto’s New Drug Approval site shows synthesis of Altratinib, a new antitumor compound which inhibits angiogenesis, tumor growth, and invasion metastasis just approved for use in glioblastoma multiforme.